TX-MARY-KAY
Mary Kay Inc., a global leader in skin care innovation, continued its ongoing support of the beauty and scientific communities recently by sponsoring the virtual 2021 Society for Investigative Dermatology (SID) Annual Meeting , helping fund the society’s virtual meeting platform. At the meeting, Mary Kay unveiled breakthrough skin health research on a botanical extract reducing retinol-related irritation via the TRPV1 receptor. The brand was also excited to announce its first-ever grants for researchers conducting groundbreaking, innovative studies in skin health and skin disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005069/en/
Mary Kay will be awarding four $25,000 grants to researchers conducting groundbreaking and innovative studies in skin health or skin diseases, which eligible applicants can apply for through August 31, 2021. The winners of the Mary Kay grants will be announced at the SID annual meeting in 2022. Through the funds, Mary Kay hopes to empower researchers to uncover new perspectives and intervention strategies in the science of dermatology.
“Mary Kay is a firm believer that a collaborative effort is crucial in identifying new discoveries and innovation,” said Dr. Lucy Gildea, Mary Kay’s Chief Scientific Officer. “Events like the annual Society for Investigative Dermatology conference bring together the brightest minds working to advance the future of the field. May Kay is excited to be part of this scientific community, and we know these research grants will further help ongoing efforts in skin research. We are thrilled to see what scientists uncover next.”
Mary Kay’s own latest research explores the combination of retinol with a plant derived TRPV1 antagonist and anti-inflammatory botanical extract in mitigating retinoid-induced irritation. Using a cosmetic formulation, Mary Kay researchers were able to demonstrate gradual retinization over a period of eight weeks. Subjects who applied the formulation not only demonstrated high tolerability to the formulation, but also a reduction in dermatologist-assessed erythema, edema, and dryness after use.
“Our Research & Development team is consistently developing new skin care solutions for women around the world,” said Dr. Gildea. “Participating in events such as the SID annual meeting allows us to learn and share relevant research so we can continue to deliver meaningful benefits and amazing products to consumers.”
The Society of Investigative Dermatology Annual Meeting is just the latest event Mary Kay has participated in 2021 with scientific and academic communities that reinforce the brand’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies and packaging designs in its global portfolio.
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 57 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005069/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Convatec Selects LTIMindtree for Strategic, AI-Powered SAP S/4HANA Transformation17.11.2025 09:30:00 CET | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced its selection as a strategic partner by Convatec, a leading global medical products and technologies company, for the implementation of SAP’s Digital Core – S/4HANA. As part of this engagement, LTIMindtree will support Convatec to implement SAP’s Digital Core – S/4HANA across its Convatec’s business operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114580133/en/ Srini Rao, EVP and Chief Business Officer - Europe at LTIMindtree & Angie Goodwin, Chief Digital Information Officer at Convatec LTIMindtree will refresh Convatec’s SAP S/4HANA landscape, streamline business processes, and enable intelligent, AI-powered digital operations. The deployment will support Convatec’s goals for process standardisation and operational efficiency, forming the foundation for its next phase of strategic technology transf
GoWit Secures Strategic Investment Led by Nuwa Capital to Drive the Next Era of AI Retail Media in EMEA17.11.2025 09:09:00 CET | Press release
GoWit, the leading AdTech company in connected commerce and retail media, announced a strategic investment round led by Nuwa Capital, with participation from existing investors Formus Capital, APY Ventures, and DCP. The investment marks a milestone in GoWit’s mission to expand AI-powered commerce and retail media network and strengthen its leadership across EMEA. Accelerating AI-Powered Retail Media Across EMEA The new capital will fuel GoWit’s expansion and the development of next-generation AI tools to enhance ad performance, data intelligence, and monetization for retailers, brands, and agencies. GoWit’s technology is trusted by leading retailers and marketplaces, including Carrefour (Turkey), Union Coop (UAE), Raneen (Egypt), Toters Delivery (Lebanon), Mumzworld (UAE), and Heureka Group (Czech Republic). The company collaborates with ecosystem partners such as Goldbach (Switzerland), Spike Media (MENA), and Akinon (EMEA), building a connected retail media infrastructure. “We built
TRU Simulation’s Bell 525 Flight Simulator Receives FAA Interim Level C Qualification17.11.2025 09:00:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc. and Bell Textron Inc. today announced its Bell 525 Full Flight Simulator (FFS) located at the Bell Training Academy received Interim Level C qualification from the Federal Aviation Administration (FAA). Bell Textron Inc. has designed and will manufacture the Bell 525 helicopter. By achieving this milestone, pilots can earn more flight hours on the Bell 525 platform ahead of the rotorcraft’s expected FAA type certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117520706/en/ TRU Simulation’s Bell 525 Flight Simulator receives FAA Interim Level C qualification “The accuracy and realism of our Flight Simulation Devices play a crucial role in ensuring that pilots can effectively translate their training into real-world scenarios,” said Jerry Messaris, vice president and general manager, TRU Simulation. “This q
Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release
Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r
Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom